Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer

European Journal of Cancer

Volumn 37, Issue 11, 2001, Pages 1359-1365

  Oka, M ^a,b   Fukuda, M ^a,c   Kinoshita, A ^d   Kuba, M ^e   Ichiki, M ^f   Rikimaru, T ^f   Soda, H ^a   Takatani, H ^g   Narasaki, F ^h   Nagashima, S ^a   Nakamura, Y I ^a   Hayashi, N ^a   Kohno, S ^a,b  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c Japanese Red Cross Nagasaki Atomic Bomb Hospital Nagasaki   (Japan)

^d Nagasaki Chuo National Hospital   (Japan)

^e National Hospital Organization Okinawa National Hospital   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Nagasaki Municipal Hospital   (Japan)

^h Nagasaki Prefectural Shimabara Hospital   (Japan)

Author keywords

Chemoradiotherapy; Cisplatin; Clinical trial; Combined modality; Lung cancer; Non small cell lung cancer; Radiation therapy; Topoisomerase I inhibitor

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ANEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; ESOPHAGITIS; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0034957417     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00099-5     Document Type: Conference Paper

References (30)

1. Combined modality therapy of lung cancer
2. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
3. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized trials
4. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small-cell lung cancer: A meta-analysis
5. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer
6. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
7. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial
8. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group
9. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies
10. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
11. Phase I study of docetaxel with concomitant thoracic radiation therapy
12. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma
13. Gemcitabine and radiation therapy for non-small-cell lung cancer
14. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
15. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex
16. Irinotecan (CPT-11): Pharmacology and clinical applications
17. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells
18. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer
19. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts
20. Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer
21. Toxicity and response criteria of the Eastern Cooperative Oncology Group
22. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small-cell lung cancer (NSCLC) - Analysis of a Radiation Therapy Oncology Group (RTOG) protocol
23. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
24. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study
25. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
26. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small-cell lung cancer
27. Risk factors of pneumonitis following chemoradiotherapy for lung cancer
28. Alternating chemotherapy and accelerated split-course irradiation in locally advanced non-small-cell lung carcinoma
29. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer